Cargando…
Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor
The papillary subtype of craniopharyngioma (CP) rarely occurs in children and commonly presents as a suprasellar lesion. Patients with papillary CPs frequently harbor the BRAF-V600E mutation, and treatment with a BRAF inhibitor results in tumor shrinkage in several patients. Herein, we report a pati...
Autores principales: | Chik, Constance L, van Landeghem, Frank K H, Easaw, Jacob C, Mehta, Vivek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064044/ https://www.ncbi.nlm.nih.gov/pubmed/33928205 http://dx.doi.org/10.1210/jendso/bvab043 |
Ejemplares similares
-
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015) -
Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020) -
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
por: Brastianos, Priscilla K., et al.
Publicado: (2014) -
In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
por: Żołek, Teresa, et al.
Publicado: (2023) -
BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma
por: Larkin, Sarah Jane, et al.
Publicado: (2014)